Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women

European Journal of Nutrition

Volumn 52, Issue 2, 2013, Pages 717-726

  López González, Ángel A ^a   Grases, Félix ^b   Monroy, Nieves ^c   Marí, Bartolome ^d   Vicente Herrero, Mâ Teófila ^e   Tur, Fernando ^b   Perelló, Joan ^b  

^a Servicio de Prevención de Riesgos Laborales de GESMA Gestión Sanitaria de Mallorca   (Spain)

^b UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^c Servicio de Prevención de Riesgos Laborales   (Spain)

^d Servicio de Medicina del Deporte Consell Insular de Mallorca   (Spain)

^e Servicio Médico de Correos   (Spain)

Author keywords

Bone mass loss; Bone mineral density; Osteoporosis; Phytate; Risk of fracture

Indexed keywords

PHYTATE;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET THERAPY; DIETARY INTAKE; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE; PROBABILITY; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; URINE LEVEL;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; CROSS-SECTIONAL STUDIES; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PHYTIC ACID; RISK ASSESSMENT; RISK FACTORS;

EID: 84878678160     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-012-0377-6     Document Type: Article

References (45)

1. Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Comm Sci Advisors Int Osteoporos Int 11:92-202
2. Haralson RH, Zuckerman JD (2009) Prevalence, health care expenditures, and orthopedic surgery workforce musculoskeletal conditions. JAMA 302:1586-1587
3. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385-397
4. Kawai M, Modder UI, Khosla S, Rosen CJ (2011) Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov 10:141-156
5. Adami S, Zamberlan N (1996) Adverse effects of bisphosphonates - a comparative review. Drug Saf 14:158-170
6. Khosla S, Burr D, Cauley J, Dempster DW, et al. (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491
7. Cummings SR, San Martin J, McClung MR, Siris ES, et al. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
8. Pak CYC, Sakhaee K, Adamshuet B, Piziak V, et al. (1995) Treatment of postmenopausal osteoporosis with slow-release sodium-fluoride. Ann Intern Med 123:401-408
9. Mamelle N, Dusan R, Martin JL, Prost A, et al. (1988) Risk-benefit ratio of sodium-fluoride treatment in primary vertebral osteoporosis. Lancet 2:361-365
10. Quattrocchi E, Kourlas H (2004) Teriparatide: a review. Clin Ther 26:841-854
11. Neer RM, Arnaud CD, Zanchetta JR, Prince R, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
12. Lindsay R, Nieves J, Formica C, Henneman E, et al. (1997) Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 350:550-555
13. Writing group for the women's health initiative investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321-333
14. Meunier PJ, Roux C, Seeman E, Ortolani S, et al. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468
15. Grases F, Simonet BM, Prieto RM, March JG (2001) Variation of InsP4, InsP5 and InsP6 levels in tissues and biological fluids depending on dietary phytate. J Nutr Biochem 12:595-601
16. Grases F, Simonet BM, Prieto RM, March JG (2001) Dietary phytate and mineral bioavailability. J Trace Elem Med Biol 15:221-228
17. Grases F, Simonet BM, Prieto RM, March JG (2001) Phytate levels in diverse rat tissues: influence of dietary phytate. Br J Nutr 86:225-231
18. Schlemmer U, Frolich W, Prieto RM, Grases F (2009) Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res 53:S330-S375
19. Grases F, Isern B, Sanchis P, Perello J, et al. (2007) Phytate acts as an inhibitor in formation of renal calculi. Front Biosci 12:2580-2587
20. Hawkins PT, Poyner DR, Jackson TR, Letcher AJ, et al. (1993) Inhibition of iron-catalyzed hydroxyl radical formation by inositol polyphosphates - a possible physiological-function for myo-inositol hexakisphosphate. Biochem J 294:929-934
21. Grases F, Sanchis P, Prieto RM, Perello J, et al. (2010) Effect of tetracalcium dimagnesium phytate on bone characteristics in ovariectomized rats. J Med Food 13:1301-1306
22. Lopez-Gonzalez AA, Grases F, Roca P, Mari B, et al. (2008) Phytate (myo-inositol hexaphosphate) and risk factors for osteoporosis. J Med Food 11:747-752
23. Lopez-Gonzalez AA, Grases F, Perello J, Tur F, et al. (2010) Phytate levels and bone parameters: a retrospective pilot clinical trial. Front Biosci (Elite Ed.) 2:1093-1098
24. Shamsuddin AM, Von Fraunhofer JA (2007) Decreasing titratable acidity of foodstuff or beverage, e.g. nutrient-enriched drinks, used to treat and prevent degeneration of teeth and other bones, involves depositing inositol phosphate composition into foodstuff or beverage. Patent. WO2007103110-A2
25. Grases F, Perello J, Isern B, Prieto RM (2004) Determination of myo-inositol hexakisphosphate (phytate) in urine by inductively coupled plasma atomic emission spectrometry. Anal Chim Acta 510:41-43
26. March JG, Simonet BM, Grases F (2001) Determination of phytic acid by gas chromatography-mass spectroscopy: application to biological samples. J Chromatogr B 757:247-255
27. Grases F, Garcia-Gonzalez R, Torres JJ, Llobera A (1998) Effects of phytic acid on renal stone formation in rats. Scand J Urol Nephrol 32:261-265
28. Conte A, Piza P, Garcia-Raja A, Grases F, et al. (1999) Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate). Arch Esp Urol 52:305-310
29. Grases F, March JG, Prieto RM, Simonet BM, et al. (2000) Urinary phytate in calcium oxalate stone formers and healthy people - dietary effects on phytate excretion. Scand J Urol Nephrol 34:162-164
30. Grases F, Prieto RM, Simonet BM, March JG (2000) Phytate prevents tissue calcifications in female rats. BioFactors 1:171-177
31. Curhan GC, Willett WC, Knight EL, Stampfer MJ (2004) Dietary factors and the risk of incident kidney stones in younger women - nurses' health study II. Arch Intern Med 164:885-891
32. Grases F, Sanchis P, Perello J, Isern B, et al. (2006) Phytate (myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. Front Biosci 1:136-142
33. Grases F, Sanchis P, Perello J, Isern B, et al. (2008) Phytate reduces age-related cardiovascular calcification. Front Biosci 13:7115-7122
34. Grases F, Sanchis P, Perello J, Isern B, et al. (2007) Effect of crystallization inhibitors on vascular calcifications induced by vitamin D - a pilot study in Sprague-Dawley rats. Circ J 71:152-1156
35. Grases F, Sanchis P, Costa-Bauza A, Bonnin O, et al. (2008) Phytate inhibits bovine pericardium calcification in vitro. Cardiovasc Pathol 17:139-145
36. Grases F, Santiago C, Simonet BM, Costa-Bauza A (2003) Sialolithiasis: mechanism of calculi formation and etiologic factors. Clin Chim Acta 334:131-136
37. Grases F, Perello J, Sanchis P, Isern B, et al. (2009) Anticalculus effect of a triclosan mouthwash containing phytate: a double-blind, randomized, three-period crossover trial. J Periodontal Res 44:616-621
38. Millan A, Pavelkova M, Sohnel O, Grases F (1998) Inhibition of calcium oxalate monohydrate crystal growth in high and low ionic strength solutions. Crystal Res Tech 33:777-786
39. Grases F, March JG (1991) Adsorption processes during crystalline growth - an analytical tool. Trends Analyt Chem 10:190-195
40. Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692-2696
41. Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643-2658
42. Russell RGG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119:S150-S162
43. William NA, Marc DM (2010) Inositol hexakisphosphate inhibits mineralization of MC3T3-E1 osteoblast cultures. Bone 46:1100-1107
44. Grases F, Simonet BM, Vucenik I, Prieto RM, et al. (2001) Absorption and excretion of orally administered inositol hexaphosphate (IP6 or phytate) in humans. BioFactors 15:53-61
45. Grases F, Simonet BM, March JG, Prieto RM (2002) Inositol hexakisphosphate in urine: the relationship between oral intake and urinary excretion. BJU Int 85:138-142 Balears